• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

Exelixis Inc EXEL 3 Star

Last Price$3.11Day Change (%)1.97%
Open Price$3.09Day Change ($)0.06
Day Range3.00–3.1652-Week Range1.26–7.40

As of Thu 3/5/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

  2. Research and Markets: Cabozantinib - Comprehensive Patent Search Portal

    Research and Markets: Cabozantinib - Comprehensive Patent Search Portal

  3. UPDATE: These are the most profitable Nasdaq biotech companies

    UPDATE: These are the most profitable Nasdaq biotech companies

  4. UPDATE: These are the most profitable Nasdaq -2-

    UPDATE: These are the most profitable Nasdaq -2-

  5. Compugen Expands and Strengthens Business Development Team

    Compugen Expands and Strengthens Business Development Team

  6. Roche Gets FDA Priority Review for Cancer Treatment

    Roche Gets FDA Priority Review for Cancer Treatment

  7. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  8. Research and Markets: Global Agriculture Farm Equipment Industry (2013-2018)

    Research and Markets: Global Agriculture Farm Equipment Industry (2013-2018)

  9. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  10. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.